Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Patent on "patent analysis"

Patent on "patent analysis"

posted on Dec 08, 2007 07:30AM

I wonder how PTSDC would score.

http://findarticles.com/p/articles/mi_m0EIN/is_2001_March_15/ai_71707777

CHI Research, Inc., a leader in analyzing competitive science and technology assets, has been awarded a patent from the U.S. Patent & Trademark Office for a method of selecting a stock portfolio based on patent quality indicators. In ten years of testing CHI's value approach has generated an average annual gain of 38%, compared to the S&P 500 Index average annual gain of 16%,and the NASDAQ `s 25%.

"Method and Apparatus for Choosing a Stock Portfolio Based on Patent Indicators" (Pat. No. 6,175,824) issued on January 16, 2001 is used to measure the impact of one of the most important intangible assets, patent quality, upon companies' future stock market valuations. The reliability of the method is impressive, having been tested over a ten-year period with hundreds of companies. CHI's portfolio of the 20 undervalued technology stocks, Investor Tech-Line(R), has out-performed the S&P 500 in 8 out of 10 years and the NASDAQ in 7 out of 10 years since 1991. (See attached performance chart.)

CHI's "824" patent is key because (1) it broadly covers the use of patent citation indicators for creating a stock portfolio, and (2) it addresses a fundamental relationship between the quality of companies' patents, as objectively measured by citation indicators, and increases in stock price that occur in subsequent years.

Share
New Message
Please login to post a reply